Yiming Biotech-B (01541) announced that the group has been approved by the National Medical Products Administration of the People's Republic of China to proceed...
According to智通财经APP, Yiming Biotech-B (01541) announced that the group has been approved by the National Medical Products Administration of the People's Republic of China to conduct a Phase II clinical trial for IMM0306 (an innovative drug bispecific antibody targeting CD47xCD20) for the treatment of lupus nephritis (LN).